Antibodies 2012, 1(1), 70-87; doi:10.3390/antib1010070


email and * email
Received: 27 April 2012; in revised form: 15 May 2012 / Accepted: 17 May 2012 / Published: 31 May 2012
(This article belongs to the Special Issue Modes of Antibody Action for Cancer Therapy)
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract: A number of cytokines have shown beneficial effects in preclinical animal models of cancer and chronic inflammatory diseases. However, cytokine treatment is often associated with severe side effects, which prevent the administration of clinically relevant doses in humans. Immunocytokines are a novel class of biopharmaceuticals, consisting of a cytokine moiety fused to monoclonal antibodies or to an antibody fragment, which selectively accumulate at the disease site and thereby enhance the therapeutic effects of cytokines. This review surveys the recent preclinical and clinical advances in the field, with a special focus on the impact of antibody formats, target antigen and cytokine moieties on the therapeutic performance in vivo. We also discuss emerging data about the possibility to combine immunocytokines with other pharmacological agents.
Keywords: immunotherapy; immunocytokines; cytokines; antibodies; antibody formats; cancer; chronic inflammatory disease
PDF Full-text Download PDF Full-Text [311 KB, uploaded 1 June 2012 07:54 CEST]

Export to BibTeX |

MDPI and ACS Style

Gutbrodt, K.L.; Neri, D. Immunocytokines. Antibodies 2012, 1, 70-87.

AMA Style

Gutbrodt KL, Neri D. Immunocytokines. Antibodies. 2012; 1(1):70-87.

Chicago/Turabian Style

Gutbrodt, Katrin L.; Neri, Dario. 2012. "Immunocytokines." Antibodies 1, no. 1: 70-87.

Antibodies EISSN 2073-4468 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert